TP53INP2 Antibody

What is the primary function of TP53INP2 in cellular processes?

TP53INP2 (Tumor Protein P53 Inducible Nuclear Protein 2) functions as a dual regulator of transcription and autophagy. It positively regulates autophagy and is essential for autophagosome formation and processing. The protein acts as a scaffold that recruits MAP1LC3A, GABARAP, and GABARAPL2 proteins and brings them to the autophagosome membrane by interacting with VMP1. There, in cooperation with the BECN1-PI3-kinase class III complex, these proteins trigger autophagosome development. Additionally, TP53INP2 acts as a transcriptional activator of THRA (thyroid hormone receptor alpha) .

What criteria should researchers consider when selecting a TP53INP2 antibody?

When selecting a TP53INP2 antibody, researchers should consider:

• Application compatibility: Verify that the antibody has been validated for your specific application (WB, IHC, ICC/IF).

• Species reactivity: Ensure the antibody recognizes TP53INP2 in your experimental species (human, mouse, rat).

• Epitope region: Different antibodies target different regions (N-terminal, C-terminal, or specific amino acid sequences). Choose based on your research question and protein domains of interest.

• Clonality: Polyclonal antibodies offer broader epitope recognition, while monoclonal antibodies provide higher specificity.

• Validation data: Review images showing performance in applications similar to yours.

• Cross-reactivity: Check for potential cross-reactivity with related proteins .

How can researchers validate the specificity of a TP53INP2 antibody?

To validate TP53INP2 antibody specificity, researchers should:

• Perform peptide competition assays: Compare staining with and without the immunizing peptide. As shown in the search results, the signal disappears when the immunizing peptide is present, confirming specificity .

• Use positive and negative controls: Test the antibody on tissues or cell lines known to express or lack TP53INP2 (e.g., BT20 cells with high expression vs. MCF7 cells with undetectable levels) .

• Knockdown validation: Compare staining between wild-type cells and TP53INP2 knockdown cells to confirm signal reduction.

• Western blot analysis: Verify that the antibody detects a band of the expected molecular weight.

• Multiple antibody approach: Use antibodies targeting different epitopes of TP53INP2 to confirm consistent results .

What are the optimal conditions for using TP53INP2 antibodies in immunohistochemistry?

For optimal immunohistochemistry (IHC) using TP53INP2 antibodies:

• Dilution: Start with manufacturer-recommended dilutions (e.g., 1/50 for paraffin-embedded tissues as indicated for ab129784) .

• Antigen retrieval: Use appropriate antigen retrieval methods, typically heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0).

• Blocking: Implement thorough blocking steps to reduce background staining.

• Incubation time and temperature: Primary antibody incubation is typically overnight at 4°C or 1-2 hours at room temperature.

• Detection system: Choose a detection system compatible with rabbit polyclonal antibodies.

• Controls: Include positive control tissues (breast carcinoma tissues have been validated) and negative controls (omitting primary antibody or using competing peptide) .

What protocols are recommended for TP53INP2 detection by Western blotting?

For Western blot detection of TP53INP2:

• Sample preparation: Prepare cell or tissue lysates using RIPA or NP-40 buffer containing protease inhibitors.

• Protein loading: Load 20-50 μg of total protein per lane.

• Gel percentage: Use 10-12% SDS-PAGE gels for optimal separation.

• Transfer: Transfer proteins to PVDF or nitrocellulose membranes.

• Blocking: Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Antibody dilution: Use the TP53INP2 antibody at recommended dilutions (typically 1:500-1:2000).

• Incubation: Incubate with primary antibody overnight at 4°C.

• Detection: Use HRP-conjugated secondary antibodies and ECL detection systems.

• Expected molecular weight: Look for the appropriate band size specific to TP53INP2 .

How can TP53INP2 antibodies be used to study the protein's role in autophagy regulation?

TP53INP2 antibodies can be employed to investigate autophagy regulation through:

• Co-immunoprecipitation (Co-IP): Use TP53INP2 antibodies to pull down the protein and analyze its interaction with autophagy-related proteins such as MAP1LC3A, GABARAP, GABARAPL2, and VMP1.

• Immunofluorescence microscopy: Perform dual staining with TP53INP2 and autophagy markers to visualize co-localization patterns during autophagy induction.

• Subcellular fractionation: Combine with Western blotting to track TP53INP2 translocation between nucleus and cytoplasm during autophagy.

• Autophagic flux assays: Use TP53INP2 antibodies alongside LC3-II and p62 antibodies to assess the impact of TP53INP2 manipulation on autophagic flux.

• Live-cell imaging: Combine with fluorescently-tagged autophagy proteins to monitor real-time dynamics of TP53INP2 during autophagosome formation .

What approaches can researchers use to investigate TP53INP2's role in death receptor signaling?

To investigate TP53INP2's role in death receptor signaling, researchers can:

• Ubiquitination assays: Use TP53INP2 antibodies in immunoprecipitation followed by ubiquitin immunoblotting to assess caspase-8 ubiquitination levels in the presence or absence of TP53INP2.

• Proximity ligation assays: Detect in situ interactions between TP53INP2, caspase-8, and TRAF6 to visualize complex formation.

• TRAIL sensitivity testing: Compare TRAIL-induced apoptosis in cell lines with different TP53INP2 expression levels, using the antibody to confirm expression status.

• Mutational analysis: Study the effects of TIM (TRAF6-interacting motif) and UIM (ubiquitin-interacting motif) mutations on TP53INP2's interaction with TRAF6 and caspase-8.

• Triple co-immunoprecipitation: Use TP53INP2 antibodies to demonstrate the formation of a complex containing TP53INP2, TRAF6, and caspase-8 .

How should researchers interpret varying TP53INP2 expression patterns across cancer cell lines?

When interpreting TP53INP2 expression across cancer cell lines:

• Correlation with apoptotic sensitivity: High TP53INP2 expression (e.g., in BT20 breast cancer cells) correlates with increased sensitivity to TRAIL-induced apoptosis (r=0.84 in breast cancer lines, r=0.87 in liver cancer lines) .

• Subcellular localization analysis: Consider both expression level and localization pattern, as nuclear-to-cytoplasmic shuttling is crucial for function.

• Context-dependent interpretation: Evaluate expression in conjunction with other death receptor pathway components.

• Cancer type specificity: TP53INP2 expression patterns and their significance may vary between cancer types.

• Functional validation: Confirm the significance of expression differences through knockdown or overexpression experiments followed by functional assays .

What are common technical challenges when working with TP53INP2 antibodies and how can they be addressed?

Common technical challenges with TP53INP2 antibodies include:

• Background staining: Optimize blocking conditions using different blocking agents (BSA, normal serum, commercial blockers) and increase washing steps.

• Epitope masking: Try different antigen retrieval methods if working with fixed tissues or cells.

• Degradation issues: Use fresh samples and add protease inhibitors during sample preparation.

• Inconsistent results between applications: Different applications may require different antibodies targeting specific epitopes; consider application-specific validated antibodies.

• Cross-reactivity: Perform careful controls, including peptide competition assays and knockdown validations.

• Nuclear protein extraction difficulties: Use specialized nuclear extraction protocols to ensure complete extraction of nuclear TP53INP2 .

How can TP53INP2 antibodies be utilized to evaluate its potential as a biomarker for TRAIL therapy response?

To evaluate TP53INP2 as a biomarker for TRAIL therapy response:

• Tissue microarray analysis: Use TP53INP2 antibodies to screen patient tumor samples for expression levels and correlate with clinical response to TRAIL-based therapies.

• Cell line profiling: Screen panels of cancer cell lines for TP53INP2 expression levels and correlate with TRAIL sensitivity (as demonstrated in breast and liver cancer cell lines) .

• Paired sample analysis: Compare TP53INP2 expression in matched pre- and post-treatment samples to assess alterations during treatment.

• Combination with other biomarkers: Analyze TP53INP2 expression alongside other death receptor pathway components to develop a comprehensive predictive panel.

• Functional validation: In cell lines with varying TP53INP2 levels, measure apoptotic response to TRAIL treatment using annexin V staining and DEVDase activity assays .

What methodological approaches can be used to study the interplay between TP53INP2's role in autophagy and apoptosis?

To investigate the interplay between TP53INP2's autophagy and apoptosis functions:

• Genetic manipulation strategies: Use CRISPR/Cas9 to generate domain-specific mutants that selectively disrupt either autophagy regulation (LIR mutations) or death receptor signaling (TIM mutations).

• Temporal analysis: Employ time-lapse microscopy with TP53INP2 antibodies to track its relocalization during the transition from autophagy to apoptosis.

• Dual pathway modulation: Combine autophagy inducers/inhibitors with death receptor ligands to assess pathway crosstalk.

• Protein-protein interaction network analysis: Use TP53INP2 antibodies for immunoprecipitation followed by mass spectrometry to identify the complete interactome under different cellular conditions.

• Single-cell analysis: Employ flow cytometry or imaging cytometry with TP53INP2 antibodies to correlate individual cell expression levels with autophagic and apoptotic markers .

How does the function of TP53INP2 compare to that of other p53-inducible proteins?

TP53INP2, while named as a p53-inducible protein, has distinct functions compared to other p53-inducible proteins:

• Dual functionality: Unlike many p53-inducible proteins that primarily function in one pathway, TP53INP2 has dual roles in transcriptional regulation and autophagy .

• Death receptor specificity: TP53INP2 specifically enhances extrinsic apoptosis through death receptors, while many other p53-inducible proteins primarily affect intrinsic apoptosis pathways .

• Scaffold function: TP53INP2 uniquely functions as a scaffold protein for caspase-8 ubiquitination by TRAF6, a mechanism not shared by other p53-related proteins .

• Subcellular shuttling: TP53INP2's ability to shuttle between nucleus and cytoplasm depending on cellular conditions distinguishes it from proteins with more stable localizations .

• TRAIL sensitivity correlation: Its levels correlate with TRAIL sensitivity in cancer cells, potentially making it a unique biomarker in this context .

What technical considerations should be addressed when comparing different commercial TP53INP2 antibodies?

When comparing different commercial TP53INP2 antibodies, researchers should consider:

• Epitope differences: Antibodies targeting different regions (N-terminal, C-terminal, or specific domains) may yield different results based on protein interactions or post-translational modifications that mask epitopes.

• Validation extent: Evaluate the comprehensiveness of validation data provided by manufacturers across different applications and cell/tissue types.

• Cross-reactivity profiles: Compare documented cross-reactivity with related proteins or in non-target species.

• Batch-to-batch consistency: Consider manufacturers with established quality control processes to ensure consistent performance.

• Application optimization: Different antibodies may require distinct optimization protocols for specific applications; compare recommended conditions.

• Publication record: Review published studies that have successfully used specific antibodies for applications similar to yours .